Biocartis partners with AstraZeneca on lung cancer diagnostics

47

Get real time updates directly on you device, subscribe now.

Biocartis partners with AstraZeneca on lung cancer diagnostics

Biocartis partners with AstraZeneca on lung cancer diagnostics
2018-11-30 13:05:01

Biocartis partners with AstraZeneca on lung cancer diagnostics 1

An employee at Biocartis enters the company’s headquarters in Mechelen April 1, 2015. REUTERS/Francois Lenoir/File Photo

(Reuters) – Belgian molecular diagnostics company Biocartis Group said on Thursday it had entered into an agreement with British drugmaker AstraZeneca to obtain faster lung cancer molecular diagnostic biomarker results in Europe.

Following the agreement, a prospective lung cancer study with Biocartis’s Idylla EGFR Mutation Test will be conducted in Belgium, France, Germany and Italy.

“We are very excited to be collaborating with AstraZeneca in the area of lung cancer … For Biocartis, this is yet another important collaboration to support the further roll-out of our Idylla platform,” Biocartis Chief Executive Officer Herman Verrelst said.

The study is aimed at determining how the Idylla platform’s features can speed up and simplify lung cancer diagnostics by delivering biomarker results faster.

Reporting by Piotr Lipinski in Gdynia, Editing by Sherry Jacob-Phillips

Our Standards:The Thomson Reuters Trust Principles.

Images are for reference only.Images gathered automatic from google.All rights on the images are with their original owners.



Biocartis partners with AstraZeneca on lung cancer diagnostics
2018-11-30 13:05:01

Images are for reference only.Images gathered automatic from google.All rights on the images are with their original owners.

Get real time updates directly on you device, subscribe now.

Comments
Loading...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy